1887

Abstract

Genetic immunization using viral vectors provides an effective means to elicit antigen-specific cellular immune responses. Several viral vectors have proven efficacious in inducing immune responses after direct injection . Among them, recombinant, self-inactivating lentiviral vectors are very attractive delivery systems, as they are able to efficiently transduce into and express foreign genes in a wide variety of mammalian cells. A self-inactivating lentiviral vector was evaluated for the delivery of human immunodeficiency virus 1 (HIV-1) envelope sequences in mice in order to elicit specific immune responses. With this aim, BALB/c mice were immunized with a single injection of self-inactivating lentiviral vectors carrying either the full-length HIV-1 Rev/Env (TY2-IIIBEnv) or the codon-optimized HIV-1 gp120 (TY2-JREnv) coding sequence. Both vectors were able to elicit specific cellular responses efficiently, as measured by gamma interferon ELISPOT and chromium-release assays, upon stimulation of splenocytes from BALB/c immunized mice. However, only the TY2-JREnv-immunized mice were able to elicit specific humoral responses, measured as anti-gp120 antibody production. These data provide the first evidence that a single, direct, administration of a lentiviral vector encoding a viral gene might represent a useful strategy for vaccine development.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81706-0
2006-06-01
2020-10-27
Loading full text...

Full text loading...

/deliver/fulltext/jgv/87/6/1625.html?itemId=/content/journal/jgv/10.1099/vir.0.81706-0&mimeType=html&fmt=ahah

References

  1. Alexander-Miller M. A., Parker K. C., Tsukui T., Pendleton C. D., Coligan J. E., Berzofsky J. A. 1996; Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes. Int Immunol 8:641–649 [CrossRef]
    [Google Scholar]
  2. Almond N., Kent K., Cranage M., Rud E., Clarke B., Stott E. J. 1995; Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345:1342–1344 [CrossRef]
    [Google Scholar]
  3. Amara R. R., Villinger F., Altman J. D. & 19 other authors 2001; Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69–74 [CrossRef]
    [Google Scholar]
  4. André S., Seed B., Eberle J., Schraut W., Bültmann A., Haas J. 1998; Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72:1497–1503
    [Google Scholar]
  5. Anson D. S. 2004; The use of retroviral vectors for gene therapy – what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther 2:9 [CrossRef]
    [Google Scholar]
  6. Baba T. W., Liska V., Khimani A. H. & 8 other authors 1999; Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 5:194–203 [CrossRef]
    [Google Scholar]
  7. Barouch D. H., Santra S., Schmitz J. E. & 26 other authors 2000; Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290:486–492 [CrossRef]
    [Google Scholar]
  8. Barouch D. H., Letvin N. L., Seder R. A. 2004; The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev 202:266–274 [CrossRef]
    [Google Scholar]
  9. Barquinero J., Eixarch H., Pérez-Melgosa M. 2004; Retroviral vectors: new applications for an old tool. Gene Ther 11:S3–S9 [CrossRef]
    [Google Scholar]
  10. Berzofsky J. A., Ahlers J. D., Janik J., Morris J., Oh S., Terabe M., Belyakov I. M. 2004; Progress on new vaccine strategies against chronic viral infections. J Clin Invest 114:450–462 [CrossRef]
    [Google Scholar]
  11. Chang L.-J., He J. 2001; Retroviral vectors for gene therapy of AIDS and cancer. Curr Opin Mol Ther 3:468–475
    [Google Scholar]
  12. Chang L.-J., Urlacher V., Iwakuma T., Cui Y., Zucali J. 1999; Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther 6:715–728 [CrossRef]
    [Google Scholar]
  13. Chinnasamy N., Treisman J. S., Oaks M. K., Hanson J. P. Jr, Chinnasamy D. 2005; Ex vivo generation of genetically modified dendritic cells for immunotherapy: implications of lymphocyte contamination. Gene Ther 12:259–271 [CrossRef]
    [Google Scholar]
  14. Cockrell A. S., Kafri T. 2003; HIV-1 vectors: fulfillment of expectations, further advancements, and still a way to go. Curr HIV Res 1:419–439 [CrossRef]
    [Google Scholar]
  15. Connolly J. B. 2002; Lentiviruses in gene therapy clinical research. Gene Ther 9:1730–1734 [CrossRef]
    [Google Scholar]
  16. Couzin J., Kaiser J. 2005; As Gelsinger case ends, gene therapy suffers another blow. Science 307:1028
    [Google Scholar]
  17. Crameri A., Whitehorn E. A., Tate E., Stemmer W. P. C. 1996; Improved green fluorescent protein by molecular evolution using DNA shuffling. Nat Biotechnol 14:315–319 [CrossRef]
    [Google Scholar]
  18. Cranage M. P., Whatmore A. M., Sharpe S. A. & 7 other authors 1997; Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 229:143–154 [CrossRef]
    [Google Scholar]
  19. Cui Y., Iwakuma T., Chang L. J. 1999; Contributions of viral splice sites and cis -regulatory elements to lentivirus vector function. J Virol 73:6171–6176
    [Google Scholar]
  20. Esslinger C., Chapatte L., Finke D., Miconnet I., Guillaume P., Lévy F., MacDonald H. R. 2003; In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8+ T cell responses. J Clin Invest 111:1673–1681 [CrossRef]
    [Google Scholar]
  21. Firat H., Zennou V., Garcia-Pons F., Ginhoux F., Cochet M., Danos O., Lemonnier F. A., Langlade-Demoyen P., Charneau P. 2002; Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy. J Gene Med 4:38–45 [CrossRef]
    [Google Scholar]
  22. Franchini G., Gurunathan S., Baglyos L., Plotkin S., Tartaglia J. 2004; Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines 3:S75–S88 [CrossRef]
    [Google Scholar]
  23. Gao F., Li Y., Decker J. M. & 11 other authors 2003; Codon usage optimization of HIV type 1 subtype C gag , pol , env , and nef genes: in vitro expression and immune responses in DNA-vaccinated mice. AIDS Res Hum Retroviruses 19:817–823 [CrossRef]
    [Google Scholar]
  24. Gómez C. E., Abaitua F., Rodríguez D., Esteban M. 2004; Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN- γ . Virus Res 105:11–22 [CrossRef]
    [Google Scholar]
  25. Goulder P. J., Rowland-Jones S. L., McMichael A. J., Walker B. D. 1999; Anti-HIV cellular immunity: recent advances towards vaccine design. AIDS 13 (Suppl. A):S121–S136
    [Google Scholar]
  26. Grignani F., Kinsella T., Mencarelli A. & 7 other authors 1998; High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res 58:14–19
    [Google Scholar]
  27. Haas J., Park E.-C., Seed B. 1996; Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 6:315–324 [CrossRef]
    [Google Scholar]
  28. Hacein-Bey-Abina S., Von Kalle C., Schmidt M. & 32 other authors 2003; LMO2 -associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415–419 [CrossRef]
    [Google Scholar]
  29. He Y., Zhang J., Mi Z., Robbins P., Falo L. D., Jr. 2005; Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol 174:3808–3817 [CrossRef]
    [Google Scholar]
  30. Heeney J. L. 2004; Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses. Expert Rev Vaccines 3:S53–S64 [CrossRef]
    [Google Scholar]
  31. Heeney J. L., Holterman L., ten Haaft P., Dubbes R., Koornstra W., Teeuwsen V., Bourquin P., Norley S., Niphuis H. 1994; Vaccine protection and reduced virus load from heterologous macaque-propagated SIV challenge. AIDS Res Hum Retroviruses 10:S117–S121
    [Google Scholar]
  32. Im E. J., Hanke T. 2004; MVA as a vector for vaccines against HIV-1. Expert Rev Vaccines 3:S89–S97 [CrossRef]
    [Google Scholar]
  33. Irwin M. J., Laube L. S., Lee V., Austin M., Chada S., Anderson C.-G., Townsend K., Jolly D. J., Warner J. F. 1994; Direct injection of a recombinant retroviral vector induces human immunodeficency virus-specific immune responses in mice and nonhuman primates. J Virol 68:5036–5044
    [Google Scholar]
  34. Iwakuma T., Cui Y., Chang L.-J. 1999; Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 261:120–132 [CrossRef]
    [Google Scholar]
  35. Jaffray A., Shephard E., van Harmelen J., Williamson C., Williamson A. L., Rybicki E. P. 2004; Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice. J Gen Virol 85:409–413 [CrossRef]
    [Google Scholar]
  36. Johnson R. P., Desrosiers R. C. 1998; Protective immunity induced by live attenuated simian immunodeficiency virus. Curr Opin Immunol 10:436–443 [CrossRef]
    [Google Scholar]
  37. Johnson P. R., Schnepp B. C., Connell M. J. & 8 other authors 2005; Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 79:955–965 [CrossRef]
    [Google Scholar]
  38. Kamantigue E., Edwards W. III, Chada S., Brumm D., Austin M., Irwin M., Mento S., Kowal K., Sajjadi N. 1996; Evidence for localization of biologically active recombinant retroviral vector to lymph nodes in mice injected intramuscularly. Gene Ther 3:128–136
    [Google Scholar]
  39. Kaul R., Rowland-Jones S. L., Kimani J. & 12 other authors 2001; New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol Lett 79:3–13 [CrossRef]
    [Google Scholar]
  40. Kim C. H., Oh Y., Lee T. H. 1997; Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells. Gene 199:293–301 [CrossRef]
    [Google Scholar]
  41. Koya R. C., Kasahara N., Favaro P. M. B., Lau R., Ta H. Q., Weber J. S., Stripecke R. 2003; Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery. J Immunother 26:451–460 [CrossRef]
    [Google Scholar]
  42. Kumar A., Narayan O. 2001; Immunization for long-term protection against AIDS using the macaque model. Virology 285:1–5 [CrossRef]
    [Google Scholar]
  43. Kung S. K. P., Bonifacino A., Metzger M. E., Ringpis G.-E., Donahue R. E., Chen I. S. Y. 2005; Lentiviral vector-transduced dendritic cells induce specific T cell response in a nonhuman primate model. Hum Gene Ther 16:527–532 [CrossRef]
    [Google Scholar]
  44. Laube L. S., Burrascano M., Dejesus C. E. & 11 other authors 1994; Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins. Hum Gene Ther 5:853–862 [CrossRef]
    [Google Scholar]
  45. Letvin N. L. 1998; What immunity can protect against HIV infection?. J Clin Invest 102:1643–1644 [CrossRef]
    [Google Scholar]
  46. Letvin N. L. 2002; Strategies for an HIV vaccine. J Clin Invest 110:15–27 [CrossRef]
    [Google Scholar]
  47. Leung L., Srivastava I. K., Kan E., Legg H., Sun Y., Greer C., Montefiori D. C., zur Megede J., Barnett S. W. 2004; Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen. AIDS 18:991–1001 [CrossRef]
    [Google Scholar]
  48. Lever A. M., Strappe P. M., Zhao J. 2004; Lentiviral vectors. J Biomed Sci 11:439–449 [CrossRef]
    [Google Scholar]
  49. Liu M., Acres B., Balloul J.-M., Bizouarne N., Paul S., Slos P., Squiban P. 2004; Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci U S A 101:14567–14571 [CrossRef]
    [Google Scholar]
  50. Mäkitalo B., Lundholm P., Hinkula J. & 9 other authors 2004; Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J Gen Virol 85:2407–2419 [CrossRef]
    [Google Scholar]
  51. Manilla P., Rebello T., Afable C. & 10 other authors 2005; Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther 16:17–25 [CrossRef]
    [Google Scholar]
  52. McMichael A., Hanke T. 2002; The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?. Nat Rev Immunol 2:283–291 [CrossRef]
    [Google Scholar]
  53. Morizono K., Xie Y., Ringpis G.-E., Johnson M., Nassanian H., Lee B., Wu L., Chen I. S. Y. 2005; Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 11:346–352 [CrossRef]
    [Google Scholar]
  54. Nagata T., Uchijima M., Yoshida A., Kawashima M., Koide Y. 1999; Codon optimization effect on translational efficiency of DNA vaccine in mammalian cells: analysis of plasmid DNA encoding a CTL epitope derived from microorganisms. Biochem Biophys Res Commun 261:445–451 [CrossRef]
    [Google Scholar]
  55. Naldini L., Blömer U., Gallay P., Ory D., Mulligan R., Gage F. H., Verma I. M., Trono D. 1996; In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263–267 [CrossRef]
    [Google Scholar]
  56. Negri D. R. M., Baroncelli S., Catone S. & 15 other authors (2004a). Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge. J Gen Virol 85:1191–1201 [CrossRef]
    [Google Scholar]
  57. Negri D. R. M., Buffa V., Leone P. & 7 other authors 2004b; Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. J Immunol Methods 291:153–163 [CrossRef]
    [Google Scholar]
  58. Norley S., Beer B., Binninger-Schinzel D., Vogel T., Siegel F., Cosma C., Konig H., Megede J. Z., Kurth R. 1996; Simian immunodeficiency virus live and inactivated experimental vaccines. AIDS Res Hum Retroviruses 12:447–449 [CrossRef]
    [Google Scholar]
  59. Ogg G. S., Jin X., Bonhoeffer S. & 12 other authors 1998; Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103–2106 [CrossRef]
    [Google Scholar]
  60. Palmowski M. J., Lopes L., Ikeda Y., Salio M., Cerundolo V., Collins M. K. 2004; Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol 172:1582–1587 [CrossRef]
    [Google Scholar]
  61. Pinto A. R., Fitzgerald J. C., Giles-Davis W., Gao G. P., Wilson J. M., Ertl H. C. J. 2003; Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol 171:6774–6779 [CrossRef]
    [Google Scholar]
  62. Pope M. 2003; Dendritic cells as a conduit to improve HIV vaccines. Curr Mol Med 3:229–242 [CrossRef]
    [Google Scholar]
  63. Ramakrishna L., Anand K. K., Mohankumar K. M., Ranga U. 2004; Codon optimization of the Tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization. J Virol 78:9174–9189 [CrossRef]
    [Google Scholar]
  64. Relph K., Harrington K., Pandha H. 2004; Recent developments and current status of gene therapy using viral vectors in the United Kingdom. BMJ 329:839–842 [CrossRef]
    [Google Scholar]
  65. Rohrlich P. S., Cardinaud S., Lulè J. & 11 other authors 2004; Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-transgenic mice and for ex vivo stimulation and expansion of CD8+ cytotoxic T cells from human peripheral blood cells. Hum Immunol 65:514–522 [CrossRef]
    [Google Scholar]
  66. Romano G., Claudio P. P., Tonini T., Giordano A. 2003; Human immunodeficiency virus type 1 (HIV-1) derived vectors: safety considerations and controversy over therapeutic applications. Eur J Dermatol 13:424–429
    [Google Scholar]
  67. Schmitz J. E., Kuroda M. J., Santra S. & 13 other authors 1999; Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283:857–860 [CrossRef]
    [Google Scholar]
  68. Schnell T., Foley P., Wirth M., Munch J., Uberla K. 2000; Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene Ther 11:439–447 [CrossRef]
    [Google Scholar]
  69. Sernicola L., Corrias F., Koanga-Mogtomo M. L. 10 other authors 1999; Long-lasting protection by live attenuated simian immunodeficiency virus in cynomolgus monkeys: no detection of reactivation after stimulation with a recall antigen. Virology 256:291–302 [CrossRef]
    [Google Scholar]
  70. Shiver J. W., Fu T.-M., Chen L. 49 other authors 2002; Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331–335 [CrossRef]
    [Google Scholar]
  71. Someya K., Xin K.-Q., Matsuo K., Okuda K., Yamamoto N., Honda M. 2004; A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag / pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity. J Virol 78:9842–9853 [CrossRef]
    [Google Scholar]
  72. Tatsis N., Ertl H. C. J. 2004; Adenoviruses as vaccine vectors. Mol Ther 10:616–629 [CrossRef]
    [Google Scholar]
  73. Titti F., Sernicola L., Geraci A. & 12 other authors 1997; Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys. J Gen Virol 78:2529–2539
    [Google Scholar]
  74. Truckenmiller M. E., Norbury C. C. 2004; Viral vectors for inducing CD8+ T cell responses. Expert Opin Biol Ther 4:861–868 [CrossRef]
    [Google Scholar]
  75. Vanniasinkam T., Ertl H. C. J. 2005; Adenoviral gene delivery for HIV-1 vaccination. Curr Gene Ther 5:203–212 [CrossRef]
    [Google Scholar]
  76. Vargas J. Jr, Gusella G. L., Najfeld V., Klotman M. E., Cara A. 2004; Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum Gene Ther 15:361–372 [CrossRef]
    [Google Scholar]
  77. Voltan R., Robert-Guroff M. 2003; Live recombinant vectors for AIDS vaccine development. Curr Mol Med 3:273–284 [CrossRef]
    [Google Scholar]
  78. Wang X., Wiley R. D., Evans T. G., Bowers W. J., Federoff H. J., Dewhurst S. 2003; Cellular immune responses to helper-free HSV-1 amplicon particles encoding HIV-1 gp120 are enhanced by DNA priming. Vaccine 21:2288–2297 [CrossRef]
    [Google Scholar]
  79. Warner J. F., Anderson C. G., Laube L., Jolly D. J., Townsend K., Chada S., St Louis D. 1991; Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells. AIDS Res Hum Retroviruses 7:645–655 [CrossRef]
    [Google Scholar]
  80. Weiss R., Teich N., Varmus H., Coffin J. 1982 Molecular biology of tumor viruses. In RNA Tumor Viruses , 2nd edn. Edited by Weiss R., Teich N., Varmus H., Coffin J. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory;
    [Google Scholar]
  81. Whitney J. B., Ruprecht R. M. 2004; Live attenuated HIV vaccines: pitfalls and prospects. Curr Opin Infect Dis 17:17–26 [CrossRef]
    [Google Scholar]
  82. Woodland D. L. 2004; Jump-starting the immune system: prime–boosting comes of age. Trends Immunol 25:98–104 [CrossRef]
    [Google Scholar]
  83. Young K. R., Teal B. E., Brooks Y., Green T. D., Bower J. F., Ross T. M. 2004; Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies. AIDS Res Hum Retroviruses 20:1259–1268 [CrossRef]
    [Google Scholar]
  84. Zack J. A., Arrigo S. J., Weitsman S. R., Go A. S., Haislip A., Chen I. S. Y. 1990; HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61:213–222 [CrossRef]
    [Google Scholar]
  85. Zaiss A.-K., Son S., Chang L.-J. 2002; RNA 3′ readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J Virol 76:7209–7219 [CrossRef]
    [Google Scholar]
  86. Zolotukhin S., Potter M., Hauswirth W. W., Guy J., Muzyczka N. 1996; A “humanized” green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 70:4646–4654
    [Google Scholar]
  87. Zufferey R., Dull T., Mandel R. J., Bukovsky A., Quiroz D., Naldini L., Trono D. 1998; Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72:9873–9880
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.81706-0
Loading
/content/journal/jgv/10.1099/vir.0.81706-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error